Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β(2)-agonist, in patients with asthma: results of a parallel-group study and a crossover study

BACKGROUND: Olodaterol is a novel, inhaled long-acting β(2)-agonist (LABA) with >24-hour duration of action investigated in asthma and chronic obstructive pulmonary disease. METHODS: Two multicentre studies examined the efficacy and safety of 4 weeks’ once-daily (QD) olodaterol (2, 5, 10 and 20 μ...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Byrne, Paul M., D’Urzo, Tony, Beck, Ekkehard, Fležar, Matjaž, Gahlemann, Martina, Hart, Lorna, Blahova, Zuzana, Toorawa, Robert, Beeh, Kai-Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539885/
https://www.ncbi.nlm.nih.gov/pubmed/26283085
http://dx.doi.org/10.1186/s12931-015-0249-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539885/
https://www.ncbi.nlm.nih.gov/pubmed/26283085
http://dx.doi.org/10.1186/s12931-015-0249-8

Ejemplares similares